| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
12,650,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exagen is engaged in commercializing a portfolio of testing products under its AVISE® brand, several of which are based on its Cell-Bound Complement Activation Products (CB-CAPs) technology. CB-CAPs assess the activation of the complement system, a biological pathway that is implicated across various autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE). Co.'s main testing product, AVISE® CTD, enables diagnosis for patients presenting with symptoms indicative of a variety of connective tissue diseases (CTDs), and other related diseases with overlapping symptoms. AVISE® CTD utilizes Co.'s CB-CAPs technology to enable the diagnosis SLE.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
90,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$241,200 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
19,522 |
19,522 |
53,341 |
72,317 |
| Total Sell Value |
$37,540 |
$37,540 |
$96,558 |
$136,333 |
| Total People Sold |
1 |
1 |
2 |
3 |
| Total Sell Transactions |
2 |
2 |
3 |
7 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2024-03-04 |
4 |
S |
$1.91 |
$24,407 |
D/D |
(12,784) |
243,749 |
|
- |
|
| Aballi John |
President and CEO |
• • – |
2024-02-29 |
4 |
A |
$1.91 |
$18,726 |
D/D |
9,804 |
600,788 |
|
- |
|
| Aballi John |
President and CEO |
• • – |
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
175,000 |
590,984 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2024-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
256,533 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2024-02-06 |
4 |
S |
$1.95 |
$13,133 |
D/D |
(6,738) |
181,533 |
|
- |
|
| Aballi John |
President and CEO |
• • – |
2023-10-17 |
4 |
S |
$1.75 |
$59,018 |
D/D |
(33,819) |
415,984 |
|
- |
|
| Aballi John |
President and CEO |
• • – |
2023-08-31 |
4 |
A |
$2.14 |
$20,998 |
D/D |
9,803 |
449,803 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2023-03-02 |
4 |
S |
$2.30 |
$8,432 |
D/D |
(3,667) |
188,271 |
|
- |
|
| Hazeltine Mark |
Chief Business Officer |
• – – |
2023-03-02 |
4 |
S |
$0.00 |
$0 |
D/D |
(3,667) |
190,205 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2023-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
191,938 |
|
- |
|
| Hazeltine Mark |
Chief Business Officer |
• – – |
2023-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
193,872 |
|
- |
|
| Hazeltine Mark |
Chief Business Officer |
• – – |
2023-02-08 |
4 |
S |
$2.69 |
$15,672 |
D/D |
(5,821) |
93,872 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2023-02-08 |
4 |
S |
$2.69 |
$15,671 |
D/D |
(5,821) |
91,938 |
|
- |
|
| Aballi John |
President and CEO |
• • – |
2022-12-08 |
4 |
B |
$2.68 |
$241,200 |
D/D |
90,000 |
440,000 |
2.81 |
- |
|
| Aballi John |
President and CEO |
• • – |
2022-10-16 |
4 |
A |
$0.00 |
$0 |
D/D |
350,000 |
350,000 |
|
- |
|
| Rocca Fortunato R. |
President and CEO |
• • – |
2022-03-01 |
4 |
D |
$7.12 |
$30,773 |
D/D |
(4,322) |
120,678 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2022-03-01 |
4 |
D |
$7.12 |
$23,076 |
D/D |
(3,241) |
97,759 |
|
- |
|
| Hazeltine Mark |
Chief Operating Officer |
• – – |
2022-03-01 |
4 |
D |
$7.12 |
$23,076 |
D/D |
(3,241) |
99,693 |
|
- |
|
| Zack Debra |
Chief Medical Officer |
• – – |
2022-03-01 |
4 |
D |
$7.12 |
$23,076 |
D/D |
(3,241) |
84,259 |
|
- |
|
| Rocca Fortunato R. |
President and CEO |
• • – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
125,000 |
|
- |
|
| Adawi Kamal |
CFO and Corporate Secretary |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
63,500 |
101,000 |
|
- |
|
| Hazeltine Mark |
Chief Operating Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
63,500 |
102,934 |
|
- |
|
| Zack Debra |
Chief Medical Officer |
• – – |
2022-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
87,500 |
|
- |
|
| Johnson Wendy S. |
Director |
– • – |
2021-09-03 |
4 |
B |
$14.02 |
$14,020 |
D/D |
1,000 |
1,000 |
2.39 |
- |
|
| Tullis James L L |
Director |
– • – |
2021-08-05 |
4 |
AS |
$10.72 |
$72,863 |
I/I |
(6,800) |
1,515,672 |
|
- |
|
103 Records found
|
|
Page 1 of 5 |
|
|
